This therapeutic effect of fluvoxamine, as well as the Sig-1R agonists SA4503 and DHEA-S, was inhibited by the Sig-1R antagonist NE-100, implying that Sig-1R activation might underlie the cognitive benefits and represent a potential target for the treatment of cognitive deficits in schizophrenia (Hashimoto et al. 2007). The gene discussed is SIGMAR1; the disease is schizophrenia.